ProQR Therapeutics (PRQR) Total Current Liabilities (2021 - 2024)
Historic Total Current Liabilities for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $41.6 million.
- ProQR Therapeutics' Total Current Liabilities rose 1296.22% to $41.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $41.6 million, marking a year-over-year increase of 1296.22%. This contributed to the annual value of $42.1 million for FY2024, which is 1380.38% up from last year.
- Latest data reveals that ProQR Therapeutics reported Total Current Liabilities of $41.6 million as of Q4 2024, which was up 1296.22% from $36.8 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Total Current Liabilities ranged from a high of $41.6 million in Q4 2024 and a low of $12658.2 during Q1 2021
- In the last 4 years, ProQR Therapeutics' Total Current Liabilities had a median value of $27.2 million in 2022 and averaged $26.3 million.
- The largest annual percentage gain for ProQR Therapeutics' Total Current Liabilities in the last 5 years was 21016805.7% (2022), contrasted with its biggest fall of 3351.97% (2022).
- Over the past 4 years, ProQR Therapeutics' Total Current Liabilities (Quarter) stood at $31.6 million in 2021, then plummeted by 32.17% to $21.4 million in 2022, then soared by 71.86% to $36.8 million in 2023, then grew by 12.96% to $41.6 million in 2024.
- Its last three reported values are $41.6 million in Q4 2024, $36.8 million for Q4 2023, and $29.0 million during Q3 2023.